Eureka Therapeutics has announced that preclinical results of its InvisiMask Human Antibody Nasal Spray in mice showed it offers up to ten hours protection against SARS-CoV-2 S pseudotyped virus infection.
Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies that harness the evolutionary power of the immune system, announced today that five abstracts, including four oral pr